Hypersensitivity Reactions to Ophthalmic Products

Ventura, M. T.; Viola, Marinella; Gaeta, Francesco; Leo, Elisabetta; Buquicchio, Rosalba; Romano, Antonino

doi:10.2174/138161206778194024

Cited by 15 publications

(6 citation statements)

References 86 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, it was unlikely that additives in vehicles prevented BAK-induced toxicity in the present study, because vehicles used in the present study did not contain HCO-40 and D-mannitol. Many ophthalmic drugs induce allergic reactions, such as allergic contact dermatitis of the periorbital region or immediate hypersensitivity reactions (Baudouin, 2005;Jappe et al, 2006;Spaeth, 2006;Ventura et al, 2006;Chaudhari and Maibach, 2007;Uter et al, 2009). In a previous study, among 332 patients patch-tested with their own topical anti-glaucoma eye drops because of suspected allergic contact dermatitis, a total of 43/332 (12.95%) showed a positive patch test reaction (Jappe et al, 2006).…”

Section: Discussionmentioning

confidence: 99%

Local toxicity of benzalkonium chloride in ophthalmic solutions following repeated applications

Okahara

Kawazu

2013

J. Toxicol. Sci.

View full text Add to dashboard Cite

-We performed repeated toxicity studies of benzalkonium chloride (BAK)-containing vehicles of ophthalmic solutions in monkeys and rabbits to assess the local toxicity of BAK after repeated applications on the ocular surface. Local toxicity of BAK was evaluated by toxicity studies in which a 0.01% BAK-containing vehicle was applied twice/day for 52 weeks, 4 times/day for 39 weeks, or 6 times/day for 13 weeks, or in which a 0.005% BAK-containing vehicle was applied 6 times/day for 52 weeks or twice/day for 4 weeks in monkeys. Local toxicity of BAK was also evaluated where a 0.01% BAK-containing vehicle was applied 6 times/day for 6 weeks, or a 0.005% BAK-containing vehicle was applied twice/day for 39 weeks or 8 times/day for 4 weeks in rabbits. These doses were chosen because BAK is generally used at concentrations up to 0.01% in ophthalmic solutions. The BAK-containing vehicle did not cause ophthalmological changes suggestive of irritation, allergy, or corneal damage. We also did not observe any histopathological changes in the eyeball, eyelid, lacrimal gland, and nasal cavity, with repeated applications of BAK for up to 52 weeks, up to 8 times/day, or at concentrations up to 0.01%, in monkeys and rabbits. Our results suggest that BAK in concentrations up to 0.01% in ophthalmic solution is non-toxic to the eyeball, its accessory organs, and the nasal cavity after long repeated applications.

show abstract

Section: Discussionmentioning

confidence: 99%

Local toxicity of benzalkonium chloride in ophthalmic solutions following repeated applications

Okahara

Kawazu

2013

J. Toxicol. Sci.

View full text Add to dashboard Cite

show abstract

“…The allergenicity of preservatives in topical ophthalmic medications should not be underestimated, even though associated reactions are rare [78].…”

Section: Ophthalmic Productsmentioning

confidence: 99%

Immediate Hypersensitivity Reactions Caused by Drug Excipients: A Literature Review

Caballero¹,

Quirce²

2020

J Investig Allergol Clin Immunol

View full text Add to dashboard Cite

The European Medicines Agency defines excipients as the constituents of a pharmaceutical form apart from the active substance. Immediate hypersensitivity reactions (IHRs) caused by excipients contained in the formulation of medications have been described. However, there are no data on the prevalence of IHRs due to drug excipients. Clinical manifestations of allergy to excipients can range from skin disorders to life-threatening systemic reactions. The aim of this study was to review the literature on allergy to pharmaceutical excipients and to record the IHRs described with various types of medications, specifically reactions due to the excipients contained in their formulations. The cases reported were sorted alphabetically by type of medication and excipient in order to obtain a list of the excipients most frequently involved for each type of medication.

show abstract

“…Le formulazioni monouso sono caratterizzate da una maggiore sicurezza e da minori effetti collaterali: al ridotto rischio di trasmissione dell'infezione al paziente successivo (13) si aggiunge, infatti, il vantaggio di evitare reazioni d'intolleranza ai conservanti e agli eccipienti presenti nelle formulazioni multiuso (14)(15)(16).…”

Section: Utilizzo DI Prodotti Monouso In Oftalmologiaunclassified

Guidelines and recommendations for the SARS-CoV-2 health emergency. Organization of ophthalmic consultations to avoid contact between healthy and asymptomatic contagious positive subjects

Troiano

Buscemi

Campos

et al. 2020

abtpn

View full text Add to dashboard Cite

The Italian Ophthalmological Society (SOI) has developed clinical practice guidelines for the care of ophthalmic patients during the coronavirus disease 2019 (COVID-19) pandemic. The aim of this document is to define guidelines that would help ophthalmologists in their clinical activities through the adoption of recommended procedures to avoid common organization and management of positive asymptomatic contagious patients and healthy people. They are based on data available in scientific literature and real clinical experience. The document underlines the unique nature of ophthalmology and its impact on people’s health and wellbeing, outlines minimal requirements to be able to perform ophthalmology procedures, discusses the use of disposable devices and materials and outlines the criteria to manage potentially contagious patients and healthy people.

show abstract

Hypersensitivity Reactions to Ophthalmic Products

Cited by 15 publications

References 86 publications

Local toxicity of benzalkonium chloride in ophthalmic solutions following repeated applications

Local toxicity of benzalkonium chloride in ophthalmic solutions following repeated applications

Immediate Hypersensitivity Reactions Caused by Drug Excipients: A Literature Review

Guidelines and recommendations for the SARS-CoV-2 health emergency. Organization of ophthalmic consultations to avoid contact between healthy and asymptomatic contagious positive subjects

Contact Info

Product

Resources

About